Latest Legal Disputes News

Triton Minerals updates investors on ongoing legal disputes over its Mozambique graphite project SSAP, rejecting a recent counterproposal and enacting strict cost-cutting measures to preserve cash.

Jatcorp anticipates a significant net loss for FY2025 driven by halted sales in China and legal disputes, yet remains cautiously optimistic about growth prospects in FY2026.

AMP Limited is set to defend itself against a new class action alleging inflated life insurance premiums and a separate dispute over a major property sale, signaling potential challenges ahead for the financial services giant.

Anax Metals has mutually withdrawn its arbitration against a cornerstone investor over exclusive marketing rights, keeping its convertible notes valid and avoiding immediate financial disruption.

Rimfire Pacific Mining has lost a key arbitration case against Golden Plains Resources and remains in a trading halt as it assesses the fallout. The company may seek a voluntary suspension to fully understand the implications and comply with ASX rules.

EML Payments has reached an in-principle agreement to settle a $37.36 million shareholder class action related to its 2020 acquisition, allowing the company to focus on its strategic growth plans.

betr Entertainment disputes the exclusion of its proxy vote in the PointsBet MIXI scheme meeting and signals a legal challenge ahead of a key court hearing. Meanwhile, betr prepares an unconditional takeover offer for PointsBet shareholders.

Dexus reports a slight 0.4% increase in portfolio valuations driven by rental growth, alongside an 18-cent estimated distribution. Meanwhile, legal proceedings involving its APAC stake face delays, clouding future outcomes.

RLF AgTech has resolved a legal dispute over a consultancy agreement, clearing the way for renewed focus on expanding its crop nutrition business domestically and internationally.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

Mayne Pharma shareholders have overwhelmingly approved the scheme of arrangement for Cosette Pharmaceuticals to acquire the company at $7.40 per share, despite ongoing legal challenges and regulatory approvals still pending.

Mayne Pharma rejects Cosette Pharmaceuticals’ claims of valid termination of their scheme deal, setting the stage for a September court showdown while urging shareholders to back the scheme in June.